CRIS Current Research Information System

ROSELLINI, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.300
NA - Nord America 1.528
EU - Europa 969
SA - Sud America 215
AF - Africa 132
Totale 6.144
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.466
SG - Singapore 957
CN - Cina 807
VN - Vietnam 702
IT - Italia 328
HK - Hong Kong 278
KR - Corea 169
BR - Brasile 160
NL - Olanda 140
BD - Bangladesh 130
DE - Germania 88
IN - India 85
SE - Svezia 70
FR - Francia 62
GB - Regno Unito 51
CI - Costa d'Avorio 48
FI - Finlandia 46
CA - Canada 43
JP - Giappone 42
SC - Seychelles 35
IE - Irlanda 34
ZA - Sudafrica 32
RU - Federazione Russa 30
CH - Svizzera 29
PH - Filippine 24
AR - Argentina 20
AT - Austria 20
TH - Thailandia 20
JO - Giordania 17
ID - Indonesia 16
BG - Bulgaria 15
PL - Polonia 13
CL - Cile 12
ES - Italia 8
CO - Colombia 7
IQ - Iraq 7
LT - Lituania 7
MX - Messico 7
TW - Taiwan 7
BE - Belgio 6
EC - Ecuador 6
PK - Pakistan 6
JM - Giamaica 5
TR - Turchia 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
DZ - Algeria 3
KG - Kirghizistan 3
KZ - Kazakistan 3
PT - Portogallo 3
SA - Arabia Saudita 3
TG - Togo 3
UA - Ucraina 3
UY - Uruguay 3
VE - Venezuela 3
AZ - Azerbaigian 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
HR - Croazia 2
IL - Israele 2
KE - Kenya 2
ML - Mali 2
MY - Malesia 2
NI - Nicaragua 2
OM - Oman 2
PE - Perù 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BY - Bielorussia 1
CD - Congo 1
CY - Cipro 1
EE - Estonia 1
EG - Egitto 1
GR - Grecia 1
HN - Honduras 1
IR - Iran 1
KW - Kuwait 1
LB - Libano 1
LV - Lettonia 1
MA - Marocco 1
MK - Macedonia 1
MU - Mauritius 1
MZ - Mozambico 1
NO - Norvegia 1
RO - Romania 1
RS - Serbia 1
SN - Senegal 1
TN - Tunisia 1
Totale 6.144
Salva come PNG Salva come JPEG
Città #
Singapore 684
Hefei 295
Hong Kong 254
Ashburn 238
Hanoi 188
Ho Chi Minh City 181
San Jose 175
Seoul 165
Santa Clara 109
Beijing 86
Council Bluffs 70
Bologna 65
Boardman 62
Los Angeles 56
New York 55
Abidjan 48
Chandler 40
Dublin 33
Milan 32
São Paulo 32
Tokyo 32
Da Nang 31
Dallas 30
Lauterbourg 29
Helsinki 28
Johannesburg 28
Bengaluru 27
Buffalo 27
Guangzhou 25
Haiphong 23
Bern 22
Redondo Beach 22
Amsterdam 21
Shanghai 18
Amman 17
Castel Maggiore 17
Nuremberg 17
Frankfurt am Main 16
Rome 16
Biên Hòa 15
Hyderabad 15
Lappeenranta 15
Montreal 15
Munich 13
Orem 13
Sofia 13
Vienna 13
Turin 12
Falkenstein 11
London 11
Tongling 11
Fairfield 10
Ninh Bình 10
Princeton 10
Chicago 9
Hải Dương 9
Phoenix 9
Southend 9
Warsaw 9
Atlanta 8
Nanjing 8
Boston 7
Florence 7
Jakarta 7
Quận Bình Thạnh 7
Rimini 7
Shenzhen 7
Thái Nguyên 7
Toronto 7
Zhengzhou 7
Bari 6
Brooklyn 6
Brussels 6
Can Tho 6
Changsha 6
Chennai 6
Columbus 6
Houston 6
Madison 6
Manchester 6
Manila 6
Moscow 6
Paris 6
Phú Thọ 6
Stockholm 6
Thái Bình 6
Bangkok 5
Berlin 5
Enschede 5
Hoofddorp 5
Mexico City 5
Modena 5
Quezon City 5
Quảng Ngãi 5
Quận Hai 5
Redmond 5
San Francisco 5
San Polo di Torrile 5
Tân Tiến 5
Wuhan 5
Totale 3.791
Salva come PNG Salva come JPEG
Nome #
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 229
Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience 206
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 178
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 176
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 176
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes 175
Dual-energy spectral CT in renal cell carcinoma: dawn of a brand-new era? 175
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives 168
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 166
Bone targeting agents in patients with metastatic prostate cancer: State of the art 166
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 164
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 163
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study 156
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 155
The value of molecular features in predicting efficacy of immuno-combinations in kidney cancer: just a drop in the ocean? 151
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience 151
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 132
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 130
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 125
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 124
The Prognostic Role of 68GA-PSMA-PET/CT in Metastatic Hormone-Sensitive Prostate Cancer: A Preliminary Analysis 118
Overall survival with adjuvant pembrolizumab in renal cell carcinoma — the shock of the lightning 117
The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory? 114
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations 107
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma 103
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study 103
Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges 95
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 95
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy 94
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma 93
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations 88
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 86
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 84
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? 83
Treating prostate cancer by antibody-drug conjugates 82
Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials 82
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers 81
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study 77
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab 76
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma? 75
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis 74
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? 73
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer 72
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis 71
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study 70
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer 68
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma 66
Pathological and Clinical Implications of Tumor Microenvironment Evaluated With Multiplex Immunohistochemistry in Testicular Embryonal Carcinoma 63
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study 62
Current androgen receptor antagonists under investigation for resistant prostate cancer 57
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study 55
Advancements of investigational agents for renal cell carcinoma: what clinical progress have we seen in the last 5 years? 54
Re: First-line Therapy for Advanced Non-Clear Cell Renal Cell Carcinoma. A Systematic Review and Meta-analysis 47
Prostate cancer and novel pharmacological treatment options - what's new for 2022? 46
Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial 41
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 41
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: A critical overview of recent evidence 40
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma 38
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials 37
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study 36
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study 30
Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2EV project 12
KIM-1 and beyond: emerging biomarkers for adjuvant immunotherapy in clear cell renal cell carcinoma 4
Totale 6.276
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.668
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.668
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202292 0 0 1 3 2 1 8 21 6 3 33 14
2022/2023365 5 15 7 17 36 35 21 19 95 11 55 49
2023/2024228 19 36 21 14 18 27 7 17 13 16 24 16
2024/20251.514 72 153 104 87 166 61 91 56 39 122 220 343
2025/20264.026 366 531 342 318 383 140 404 144 649 287 185 277
2026/202739 39 0 0 0 0 0 0 0 0 0 0 0
Totale 6.276